Idasanutlin
- Generic Name
- Idasanutlin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C31H29Cl2F2N3O4
- CAS Number
- 1229705-06-9
- Unique Ingredient Identifier
- QSQ883V35U
- Background
Idasanutlin has been used in trials studying the treatment of Neoplasms, Non-Hodgkin's Lymphoma, Leukemia, Myeloid, Acute, Recurrent Plasma Cell Myeloma, and Neoplasms, Leukemia, Acute Myeloid Leukemia.
- Associated Conditions
- -
- Associated Therapies
- -
Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- St. Jude Children's Research Hospital
- Registration Number
- NCT05952687
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 920
- Registration Number
- NCT04589845
- Locations
- 🇺🇸
Southern Cancer Center, Daphne, Alabama, United States
🇺🇸Western Regional Medical Center at Cancer Treatment Centers of America, Goodyear, Arizona, United States
🇺🇸Hoag Memorial Hospital, Newport Beach, California, United States
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
- First Posted Date
- 2019-07-23
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 38
- Registration Number
- NCT04029688
- Locations
- 🇺🇸
Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States
🇺🇸Lucile Packard Children's Hospital at Stanford University; Thoracic Oncology, Palo Alto, California, United States
🇺🇸Arnold Palmer Hosp-Children, Orlando, Florida, United States
A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
- Conditions
- Interventions
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT03850535
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
- First Posted Date
- 2018-06-25
- Last Posted Date
- 2021-08-11
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT03566485
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 96
- Registration Number
- NCT03555149
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, France
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT03362723
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸Yale Cancer Center; Medical Oncology, New Haven, Connecticut, United States
🇨🇦Jewish General Hospital / McGill University, Montreal, Quebec, Canada
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera
- First Posted Date
- 2017-09-19
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 27
- Registration Number
- NCT03287245
- Locations
- 🇺🇸
University of Kansas Cancer Center; Westwood Cancer Center/BMT Output Clinic, Kansas City, Kansas, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸University of Texas Health Sciences Center in San Antonio, San Antonio, Texas, United States
NCT Neuro Master Match - N²M² (NOA-20)
- Conditions
- Interventions
- First Posted Date
- 2017-05-18
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- University Hospital Heidelberg
- Target Recruit Count
- 228
- Registration Number
- NCT03158389
- Locations
- 🇩🇪
University Hospital Mainz, Neurosurgery, Mainz, Germany
🇩🇪University Hospital Heidelberg, Neurology Clinic, Heidelberg, Germany
🇩🇪University Hospital Frankfurt, Neurooncology, Frankfurt am Main, Germany
A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Interventions
- First Posted Date
- 2017-05-01
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT03135262
- Locations
- 🇺🇸
Mount Sinai Medical Center, New York, New York, United States
🇦🇺Prince of Wales Hospital, Randwick, New South Wales, Australia
🇦🇺Westmead Hospital, Westmead, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.